Literature DB >> 20307511

RNAi therapeutics for CNS disorders.

Ryan L Boudreau1, Beverly L Davidson.   

Abstract

RNA interference (RNAi) is a process of sequence-specific gene silencing and serves as a powerful molecular tool to manipulate gene expression in vitro and in vivo. RNAi technologies have been applied to study gene function and validate drug targets. Researchers are investigating RNAi-based compounds as novel therapeutics to treat a variety of human diseases that are currently lacking sufficient treatment. To date, numerous studies support that RNAi therapeutics can improve disease phenotypes in various rodent models of human disease. Here, we focus on the development of RNAi-based therapies aimed at treating neurological disorders for which reduction of mutant or toxic gene expression may provide clinical benefit. We review RNAi-based gene-silencing strategies, proof-of-concept studies testing therapeutic RNAi for CNS disorders, and highlight the most recent research aimed at transitioning RNAi-based therapeutics toward clinical trials. Copyright (c) 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20307511     DOI: 10.1016/j.brainres.2010.03.038

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  16 in total

Review 1.  Oligonucleotide therapeutic approaches for Huntington disease.

Authors:  Dinah W Y Sah; Neil Aronin
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

2.  An in silico approach to design potential siRNA molecules for ICP22 (US1) gene silencing of different strains of human herpes simplex 1.

Authors:  Suza Mohammad Nur; Mohammad Al Amin; Rashel Alam; Md Anayet Hasan; Md Amzad Hossain; Adnan Mannan
Journal:  J Young Pharm       Date:  2013-06-20

Review 3.  RNAi medicine for the brain: progresses and challenges.

Authors:  Ryan L Boudreau; Edgardo Rodríguez-Lebrón; Beverly L Davidson
Journal:  Hum Mol Genet       Date:  2011-03-31       Impact factor: 6.150

4.  RNA interference improves myopathic phenotypes in mice over-expressing FSHD region gene 1 (FRG1).

Authors:  Lindsay M Wallace; Sara E Garwick-Coppens; Rossella Tupler; Scott Q Harper
Journal:  Mol Ther       Date:  2011-07-05       Impact factor: 11.454

5.  An α-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons.

Authors:  Christina E Khodr; Mohan K Sapru; Jyothi Pedapati; Ye Han; Neva C West; Adrian P Kells; Krystof S Bankiewicz; Martha C Bohn
Journal:  Brain Res       Date:  2011-04-22       Impact factor: 3.252

6.  Broad therapeutic benefit after RNAi expression vector delivery to deep cerebellar nuclei: implications for spinocerebellar ataxia type 1 therapy.

Authors:  Megan S Keiser; Ryan L Boudreau; Beverly L Davidson
Journal:  Mol Ther       Date:  2013-12-12       Impact factor: 11.454

Review 7.  The role of IκB kinase complex in the neurobiology of Huntington's disease.

Authors:  Ali Khoshnan; Paul H Patterson
Journal:  Neurobiol Dis       Date:  2011-05-05       Impact factor: 5.996

8.  A microRNA embedded AAV α-synuclein gene silencing vector for dopaminergic neurons.

Authors:  Ye Han; Christina E Khodr; Mohan K Sapru; Jyothi Pedapati; Martha C Bohn
Journal:  Brain Res       Date:  2011-02-19       Impact factor: 3.252

Review 9.  Proteinopathies associated to repeat expansion disorders.

Authors:  Anthony Fourier; Isabelle Quadrio
Journal:  J Neural Transm (Vienna)       Date:  2022-01-24       Impact factor: 3.575

10.  Cell- and region-specific miR30-based gene knock-down with temporal control in the rat brain.

Authors:  Beihui Liu; Haibo Xu; Julian F R Paton; Sergey Kasparov
Journal:  BMC Mol Biol       Date:  2010-12-06       Impact factor: 2.946

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.